Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 849

1.
2.

Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis.

Sarasin FP, Bounameaux H.

Arch Intern Med. 1996 Aug 12-26;156(15):1661-8. Erratum in: Arch Intern Med 1996 Nov 25;156(21):2487.

PMID:
8694664
[PubMed - indexed for MEDLINE]
3.
4.

Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.

Dunn CJ, Goa KL.

Pharmacoeconomics. 1996 Aug;10(2):179-90.

PMID:
10163420
[PubMed - indexed for MEDLINE]
5.

Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement.

Dahl OE, Pleil AM.

J Thromb Haemost. 2003 May;1(5):896-906.

PMID:
12871354
[PubMed - indexed for MEDLINE]
6.

[Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].

Míka P, Behounek J, Skoták M, Nevsímal L.

Acta Chir Orthop Traumatol Cech. 2004;71(4):237-44. Czech.

PMID:
15456102
[PubMed - indexed for MEDLINE]
7.

Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.

Bell GK, Goldhaber SZ.

Vasc Med. 2001;6(1):23-9.

PMID:
11358156
[PubMed - indexed for MEDLINE]
8.

Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.

Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG.

Arch Intern Med. 1997 Feb 10;157(3):298-303.

PMID:
9040296
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.

Menzin J, Colditz GA, Regan MM, Richner RE, Oster G.

Arch Intern Med. 1995 Apr 10;155(7):757-64.

PMID:
7695464
[PubMed - indexed for MEDLINE]
10.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
[PubMed - indexed for MEDLINE]
11.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033
[PubMed - indexed for MEDLINE]
12.

A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.

Hawkins DW, Langley PC, Krueger KP.

Clin Ther. 1998 Jan-Feb;20(1):182-95.

PMID:
9522114
[PubMed - indexed for MEDLINE]
13.

Duration of venous thromboembolism prophylaxis after surgery.

Kearon C.

Chest. 2003 Dec;124(6 Suppl):386S-392S. Review.

PMID:
14668422
[PubMed - indexed for MEDLINE]
14.

A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.

Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH.

J Bone Joint Surg Am. 2000 Jul;82-A(7):929-38.

PMID:
10901307
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.

Levin LA, Bergqvist D.

Pharmacoeconomics. 2001;19(5 Pt 2):589-97. Review.

PMID:
11465303
[PubMed - indexed for MEDLINE]
16.

The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.

Skedgel C, Goeree R, Pleasance S, Thompson K, O'brien B, Anderson D.

J Bone Joint Surg Am. 2007 Apr;89(4):819-28. Review.

PMID:
17403806
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.

O'Brien BJ, Anderson DR, Goeree R.

CMAJ. 1994 Apr 1;150(7):1083-90.

PMID:
8137188
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].

Arreola-Ornelas H, Rosado-Buzzo A, García-Mollinedo L, Dorantes Aguilar J, Muciño-Ortega E, Mould-Quevedo JF.

Cir Cir. 2012 Sep-Oct;80(5):411-8. Spanish.

PMID:
23351443
[PubMed - indexed for MEDLINE]
19.

Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.

Friedman RJ, Dunsworth GA.

Clin Orthop Relat Res. 2000 Jan;(370):171-82.

PMID:
10660711
[PubMed - indexed for MEDLINE]
20.

Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Schädlich PK, Kentsch M, Weber M, Kämmerer W, Brecht JG, Nadipelli V, Huppertz E.

Pharmacoeconomics. 2006;24(6):571-91.

PMID:
16761905
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk